A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2017
At a glance
- Drugs Luminespib (Primary) ; Lapatinib; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Aug 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 May 2012 Actual initiation date (1 Jul 2011) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.